Imiglucerase

Imiglucerase
Clinical data
Trade names	Cerezyme
AHFS/Drugs.com	Monograph
MedlinePlus	a601149
License data	EU EMA: by INN; US DailyMed: Imiglucerase;
Routes of; administration	Intravenous infusion
ATC code	A16AB02 (WHO) ;
Legal status
Legal status	US: ℞-only; EU: Rx-only;
Pharmacokinetic data
Metabolism	probably proteolysis
Elimination half-life	3.6–10.4 min
Identifiers
	IUPAC name Human beta-glucocerebrosidase;
CAS Number	154248-97-2 ;
DrugBank	DB00053 ;
ChemSpider	none;
UNII	Q6U6J48BWY;
KEGG	D02810 ;
ChEMBL	ChEMBL1201632 ;
Chemical and physical data
Formula	C2532H3854N672O711S16
Molar mass	55597.4 g·mol−1 (unglycosylated)
	(what is this?) (verify)

Imiglucerase is a medication used in the treatment of Gaucher's disease.

It is a recombinant DNA-produced analogue of the human enzyme β-glucocerebrosidase. Cerezyme is a freeze-dried medicine containing imiglucerase, manufactured by Genzyme Corporation. It is given intravenously after reconstitution as a treatment for Type 1 and Type 3 Gaucher's disease. It is available in formulations containing 200 or 400 units per vial. The specific activity of highly purified human enzyme is 890,000 units/mg, meanwhile the enzyme activity produced by recombinant DNA technology is approximately 40 units/mg. A typical dose is 2.5U/kg every two weeks, up to a maximum of 60 U/kg once every two weeks, and safety has been established from ages 2 and up. It is one of more expensive medications, with an annual cost of $200,000 per person in the United States. Imiglucerase has been granted orphan drug status in the United States, Australia, and Japan.

Cerezyme was one of the drugs manufactured at Genzyme's Allston, Massachusetts plant, for which production was disrupted in 2009 after contamination with Vesivirus 2017.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.